Reformulated Raltegravir

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in HIV Infection

View Full Landscape

Drug Information

Target Indication

HIV Infection

Clinical Trial

NCT02131233

Last updated: 12/18/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/19/2007

Isentress

Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.

Accelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK0966; Rofecoxib / Duration of Treatment: 156 weeksPhase 3

Colorectal Adenoma

PalbociclibPhase 3

Renal Cell Carcinoma

Vancomycin (or equivalent)Phase 3

Acute Hematogenous Osteomyelitis

Sitagliptin 100 mgPhase 3

Type 2 Diabetes Mellitus

VoglibosePhase 3

Diabetes Mellitus, Non-Insulin-Dependent

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts